ITCI — Intra-Cellular Therapies Share Price
- $6.90bn
- $6.42bn
- $464.37m
- 66
- 14
- 73
- 50
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 524.04 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 11.5 | ||
Price to Tang. Book | 11.5 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 13.42 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -21.55% | ||
Return on Equity | -18.07% | ||
Operating Margin | -25.67% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.06 | 22.81 | 83.8 | 250.31 | 464.37 | 663.49 | 931.92 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Directors
- Lawrence Hineline CFO (64)
- Michael Halstead EVP (47)
- Mark Neumann EVP (58)
- Suresh Durgam SVP (52)
- Robert Van Nostrand LED (63)
- Sharon Mates DRC (68)
- Christopher Alafi IND (57)
- Joel Marcus IND (73)
- Michael Rawlins IND (80)
- Rory Riggs IND (68)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 29th, 2012
- Public Since
- January 31st, 2014
- No. of Shareholders
- 73
- No. of Employees
- 610
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 105,574,855
- Address
- 430 East 29th Street, Suite 900, NEW YORK, 10016
- Web
- https://www.intracellulartherapies.com/
- Phone
- +1 6464409333
- Auditors
- Ernst & Young LLP
Upcoming Events for ITCI
Intra-Cellular Therapies Inc Annual Shareholders Meeting
Q2 2024 Intra-Cellular Therapies Inc Earnings Release
Q3 2024 Intra-Cellular Therapies Inc Earnings Release
Similar to ITCI
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
As of Today at 16:03 UTC, shares in Intra-Cellular Therapies are trading at $65.32. This share price information is delayed by 15 minutes.
Shares in Intra-Cellular Therapies last closed at $65.32 and the price had moved by +4.65% over the past 365 days. In terms of relative price strength the Intra-Cellular Therapies share price has underperformed the S&P500 Index by -17.35% over the past year.
The overall consensus recommendation for Intra-Cellular Therapies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Intra-Cellular Therapies does not currently pay a dividend.
Intra-Cellular Therapies does not currently pay a dividend.
Intra-Cellular Therapies does not currently pay a dividend.
To buy shares in Intra-Cellular Therapies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $65.32, shares in Intra-Cellular Therapies had a market capitalisation of $6.90bn.
Here are the trading details for Intra-Cellular Therapies:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ITCI
Based on an overall assessment of its quality, value and momentum Intra-Cellular Therapies is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Intra-Cellular Therapies is $91.64. That is 40.29% above the last closing price of $65.32.
Analysts covering Intra-Cellular Therapies currently have a consensus Earnings Per Share (EPS) forecast of -$0.53 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intra-Cellular Therapies. Over the past six months, its share price has underperformed the S&P500 Index by -5.32%.
As of the last closing price of $65.32, shares in Intra-Cellular Therapies were trading +4.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Intra-Cellular Therapies PE ratio based on its reported earnings over the past 12 months is 524.04. The shares last closed at $65.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Intra-Cellular Therapies' management team is headed by:
- Lawrence Hineline - CFO
- Michael Halstead - EVP
- Mark Neumann - EVP
- Suresh Durgam - SVP
- Robert Van Nostrand - LED
- Sharon Mates - DRC
- Christopher Alafi - IND
- Joel Marcus - IND
- Michael Rawlins - IND
- Rory Riggs - IND